|
rs1003897973
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
We failed to confirm earlier reports of increased cervical cancer susceptibility in women who harbor the p53 P72R allele.
|
12142377 |
2002 |
|
rs1007541
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Stratification according to FIGO staging revealed that the minor allele of rs1007541 was more frequent among advanced tumor stage patients, with 11-fold increased risk of CC [P < 0.0001; OR (95 % CI) = 11.32 (7.46-17.18)].
|
27844329 |
2017 |
|
rs1030389
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the SNPs after stratification based on CC clinical stage and subtype revealed that rs1048512, rs6659346, rs217727, rs9931702, and rs9302648 were associated with CC risk in clinical stages I-II; rs2862833, rs2732044, rs1030389, and rs1045935 were associated with CC risk in clinical stages III-IV; and rs217727, rs9931702, and rs9302648 were associated with CC risk in squamous carcinomas.
|
27765929 |
2016 |
|
rs1041981
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
A significant association of CxCa with various polymorphisms was observed: rs1800797 in the IL-6 gene (odds ratio [OR] = 0.88, 95% confidence intervals [CI]: 0.79-0.99); rs1041981 in the LTA gene (OR = 0.87, 95% CI: 0.78-0.98), and rs9344 in the CCND1 gene (OR = 1.14, 95% CI: 1.02-1.27), for those individuals carrying the rare allele.
|
19585495 |
2009 |
|
rs10426502
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
The stratified analysis showed that <i>TNFAIP8L1</i>-rs10426502, -rs1060555, and <i>FLT1</i>-rs9513111 were associated with a decreased risk of cervical cancer amongst people older than 43 years.
|
31289124 |
2019 |
|
rs1042725
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
The minor allele "C" of rs1042725 in HMGA2 was associated with an increased risk of CC in the allele, dominant and log-additive models.
|
27677077 |
2016 |
|
rs1045935
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the SNPs after stratification based on CC clinical stage and subtype revealed that rs1048512, rs6659346, rs217727, rs9931702, and rs9302648 were associated with CC risk in clinical stages I-II; rs2862833, rs2732044, rs1030389, and rs1045935 were associated with CC risk in clinical stages III-IV; and rs217727, rs9931702, and rs9302648 were associated with CC risk in squamous carcinomas.
|
27765929 |
2016 |
|
rs1047840
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
These findings indicate that the SNPs of EXO1 K589E may contribute to cervical cancer carcinogenesis in Chinese populations.
|
22146767 |
2012 |
|
rs1048512
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the SNPs after stratification based on CC clinical stage and subtype revealed that rs1048512, rs6659346, rs217727, rs9931702, and rs9302648 were associated with CC risk in clinical stages I-II; rs2862833, rs2732044, rs1030389, and rs1045935 were associated with CC risk in clinical stages III-IV; and rs217727, rs9931702, and rs9302648 were associated with CC risk in squamous carcinomas.
|
27765929 |
2016 |
|
rs1048638
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
In conclusion, the finding that the <i>CA9</i> </span>SNP rs1</span>048638 exerts its action through duplexes of the miR-34a and <i>CA9</i> 3'-UTRs and plays a vital role in cervical cancer in Taiwanese women may be applicable to translational medicine.
|
29100431 |
2017 |
|
rs1049216
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
These data indicate that through upregulating the expression of caspase-3, the TT genotype of caspase-3 rs1049216 can be associated with not only the risk of cervical cancer but also the progression of this cancer.
|
28114230 |
2017 |
|
rs1058808
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b> Our results suggested that the combination of <i>HER2</i> rs1136201and rs1058808 was significantly associated with the susceptibility of CCa.
|
30719131 |
2019 |
|
rs1059234
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
The AGT haplotype formed by three p21 SNPs in LD (rs1801270, rs3176352 and rs1059234) also provided a protective effect in development of cervical cancer in this population.
|
23231583 |
2012 |
|
rs1060555
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
The stratified analysis showed that <i>TNFAIP8L1</i>-rs10426502, -rs1060555, and <i>FLT1</i>-rs9513111 were associated with a decreased risk of cervical cancer amongst people older than 43 years.
|
31289124 |
2019 |
|
rs10802996
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
This is the first study on the role of EXO1 K589E (rs1047840) and EXO1 C908G (rs10802996) polymorphisms in cervical cancer in a Chinese population.
|
22146767 |
2012 |
|
rs10815144
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two SNPs in JAK2 and one SNP in STAT6 showed significant allelic association with cervical cancer in the stage 1 discovery dataset and were replicated in the larger joint analysis stage 2 dataset (JAK2 rs10815144, P=0.0029 and rs12349785, P=0.0058; and STAT6 rs3024971, P=0.0127).
|
25127987 |
2014 |
|
rs10893506
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
The polymorphism analysis showed that at SNP rs10893506, genotypes CC and CT of the ST3GAL4 B3 promoter were associated with the presence of premalignant lesions (OR=2.89; 95%CI 1.72-4.85) and cervical cancer (OR=2.23; 95%CI 1.27-3.91).
|
24606438 |
2014 |
|
rs11064
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that the TNFAIP8-rs11064 variant GG genotype was associated with an increased risk of cervical cancer compared with AA/AG genotypes (adjusted odds ratio = 2.16, 95% confidence interval = 1.16-4.03, P = 0.015).
|
23299407 |
2013 |
|
rs1110839
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Logistic regression analyses revealed that variant allele T of rs4848320 (recessive model: adjusted OR = 0.61, 95 % CI = 0.38-0.97, P = 0.027) and G of rs1110839 (additive model: adjusted OR = 0.88, 95 % CI = 0.79-0.99, P = 0.032) were associated with decreased risk of cervical cancer.
|
27225188 |
2016 |
|
rs11125
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our findings provide evidence that allele C of rs4652 and allele T of rs11125 in the galectin-3 gene may be risk factors for cervical cancer.
|
28848207 |
2017 |
|
rs11202058
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Rs7083506 and rs11202058 polymorphisms of hWAPL and their haplotype T-A were associated with cervical cancer.
|
26722608 |
2015 |
|
rs1126497
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Compared with the rs1126497 CC genotype, CT genotype had a significantly increased risk of cervical cancer</span> (Crude OR = 1.70; 95% CI = 1.33-2.20; adjusted OR = 1.72; 95% CI = 1.33-2.22), the TT carriers had a further increased risk of cervical cancer (Crude OR = 1.94; 95% CI = 1.01-3.72; adjusted OR = 1.96; 95%CI = 1.01-3.81), and there was a trend for an allele dose effect on risk of cervical cancer (P < 0.001).
|
22322561 |
2012 |
|
rs1131445
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
These results support our hypothesis that miRSNPs constitute a susceptibility factor for cervical cancers. rs1131445 affects IL-16 expression by interfering with the suppressive function of miR135b and this variant is significantly associated with cervical cancer risk.
|
24465869 |
2014 |
|
rs1136201
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Employing PCR-RFLPs, we examined the distribution of HER2 Ile655Val (rs 1136201) genotypes and alleles in patients with advanced cervical cancer (n=109) and controls (n=220).
|
20026098 |
2010 |
|
rs1141718
|
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genotypic association of both Val-9Ala and Ile58Thr polymorphisms with cervical cancer and breast cancer of these patients comparing to healthy women was not statistically significant (p<0.05).
|
23886214 |
2013 |